JM Boyett

Clinical and biologic features predict a poor prognosis in acute lymphoid leukemias in infants: a Pediatric Oncology Group Study

W M Crist, Jeanette Pullen, JM Boyett et al. · Blood · 1986 · 152 citations · Full text

Medicine, Oncology, Pediatrics +12

Extended triple intrathecal chemotherapy trial for prevention of CNS relapse in good-risk and poor-risk patients with B-progenitor acute lymphoblastic leukemia: a Pediatric Oncology Group study.

Jeanette Pullen, JM Boyett, Jonathan J. Shuster et al. · Journal of Clinical Oncology · 1993 · 132 citations

Medicine, Pediatrics, Pharmacotherapy +17

L-asparaginase may potentiate the leukemogenic effect of the epipodophyllotoxins.

Pui Ch, Relling Mv, Behm Fg et al. · PubMed · 1995 · 79 citations

Medicine, Pharmacology, Toxicology +3

Pediatric oncology group experience with modified LSA2-L2 therapy in 107 children with non-Hodgkin's lymphoma (Burkitt's lymphoma excluded)

Margaret P. Sullivan, JM Boyett, Jeanette Pullen et al. · Cancer · 1985 · 71 citations · Full text

Medicine, Oncology, Pediatrics +11

Modified LSA2-L2 treatment in 53 children with E-rosette-positive T- cell leukemia: results and prognostic factors (a Pediatric Oncology Group Study)

DJ Pullen, MP Sullivan, JM Falletta et al. · Blood · 1982 · 66 citations · Full text

Medicine, Oncology, Pediatrics +10